SpringerLink - Cancer Causes and Control, Online First™

Original paper
Cancer Causes and Control
DOI: 10.1007/s10552-010-9613-7Online First™

Polymorphisms in oxidative stress and inflammation pathway genes, low-dose ionizing radiation, and the risk of breast cancer among US radiologic technologists
Sara J. Schonfeld, Parveen Bhatti, Elizabeth E. Brown, Martha S. Linet, Steven L. Simon, Robert M. Weinstock, Amy A. Hutchinson, Marilyn Stovall, Dale L. Preston and Bruce H. Alexander, et al.

Abstract

Objective
Ionizing radiation, an established breast cancer risk factor, has been shown to induce oxidative damage and chronic inflammation. Polymorphic variation in oxidative stress and inflammatory-mediated pathway genes may modify radiation-related breast cancer risk.

Methods
We estimated breast cancer risk for 28 common variants in 16 candidate genes involved in these pathways among 859 breast cancer cases and 1,083 controls nested within the US Radiologic Technologists cohort. We estimated associations between occupational and personal diagnostic radiation exposures with breast cancer by modeling the odds ratio (OR) as a linear function in logistic regression models and assessed heterogeneity of the dose–response across genotypes.

Results
There was suggestive evidence of an interaction between the rs5277 variant in PTGS2 and radiation-related breast cancer risk. The excess OR (EOR)/Gy from occupational radiation exposure = 5.5 (95%CI 1.2–12.5) for the GG genotype versus EOR/Gy < 0 (95%CI < 0–3.8) and EOR/Gy < 0 (95%CI < 0–14.8) for the GC and CC genotypes, respectively, (p interaction = 0.04). The association between radiation and breast cancer was not modified by other SNPs examined.

Conclusions
This study suggests that variation in PTGS2 may modify the breast cancer risk from occupational radiation exposure, but replication in other populations is needed to confirm this result.

Keywords PTGS2 - COX-2 - Inflammation - Breast cancer - Radiation

open here please:
SpringerLink - Cancer Causes and Control, Online First™